T cells play pathophysiologic roles in kidney ischemia-reperfusion injury (IRI), and the nuclear factor erythroid 2-related factor 2/kelch-like ECH-associated protein 1 (Nrf2/Keap1) pathway regulates T cell responses. We hypothesized that clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9)-mediated Keap1-knockout (KO) augments Nrf2 antioxidant potential of CD4+ T cells, and that Keap1-KO CD4+ T cell immunotherapy protects from kidney IRI.
Results:
CD4+ T cell Keap1-KO resulted in significant increase of Nrf2 target genes NAD(P)H quinone dehydrogenase 1, heme oxygenase 1, glutamate-cysteine ligase catalytic subunit, and glutamate-cysteine ligase modifier subunit. Keap1-KO cells displayed no signs of exhaustion, and had significantly lower levels of interleukin 2 (IL2) and IL6 in normoxic conditions, but increased interferon gamma in hypoxic conditions in vitro. In vivo, adoptive transfer of Keap1-KO CD4+ T cells before IRI improved kidney function in T cell-deficient nu/nu mice compared with mice receiving unedited control CD4+ T cells. Keap1-KO CD4+ T cells isolated from recipient kidneys 24 h post IR were less activated compared with unedited CD4+ T cells, isolated from control kidneys.
Innovation:
Editing Nrf2/Keap1 pathway in murine T cells using CRISPR/Cas9 is an innovative and promising immunotherapy approach for kidney IRI and possibly other solid organ IRI.
Conclusion:
CRISPR/Cas9-mediated Keap1-KO increased Nrf2-regulated antioxidant gene expression in murine CD4+ T cells, modified responses to in vitro hypoxia and in vivo kidney IRI. Gene editing targeting the Nrf2/Keap1 pathway in T cells is a promising approach for immune-mediated kidney diseases.
Get full access to this article
View all access options for this article.
References
1.
AgarwalA, DongZ, HarrisR, et al.Cellular and molecular mechanisms of AKI. J Am Soc Nephrol, 2016; 27:1288–1299.
2.
AndersHJ, WilkensL, SchramlB, et al.One concept does not fit all: The immune system in different forms of acute kidney injury. Nephrol Dial Transplant, 2021; 36:29–38.
3.
AsconDB, Lopez-BrionesS, LiuM, et al.Phenotypic and functional characterization of kidney-infiltrating lymphocytes in renal ischemia reperfusion injury. J Immunol, 2006; 177:3380–3387.
4.
BattistoneMA, MendelsohnAC, SpallanzaniRG, et al.Proinflammatory P2Y14 receptor inhibition protects against ischemic acute kidney injury in mice. J Clin Invest, 2020; 130:3734–3749.
5.
BeachTE, PragHA, PalaL, et al.Targeting succinate dehydrogenase with malonate ester prodrugs decreases renal ischemia reperfusion injury. Redox Biol, 2020; 36:101640.
6.
BlackLM, LeverJM, TraylorAM, et al.Divergent effects of AKI to CKD models on inflammation and fibrosis. Am J Physiol Renal Physiol, 2018; 315:F1107–F1118.
7.
Borges da SilvaH, FonsecaR, AlvarezJM, et al.IFN-γ priming effects on the maintenance of effector memory CD4(+) T cells and on phagocyte function: Evidences from infectious diseases. J Immunol Res, 2015; 2015:202816.
8.
BurneMJ, DanielsF, El GhandourA, et al.Identification of the CD4(+) T cell as a major pathogenic factor in ischemic acute renal failure. J Clin Invest, 2001; 108:1283–1290.
9.
ChungS, OverstreetJM, LiY, et al.TGF-β promotes fibrosis after severe acute kidney injury by enhancing renal macrophage infiltration. JCI Insight, 2018; 3:e123563.
10.
D'AlessioFR, KurzhagenJT, RabbH. Reparative T lymphocytes in organ injury. J Clin Invest, 2019; 129:2608–2618.
11.
de ZeeuwD, AkizawaT, AudhyaP, et al.Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med, 2013; 369:2492–2503.
12.
DellepianeS, LeventhalJS, CravediP. T Cells and acute kidney injury: A two-way relationship. Front Immunol, 2020; 11:1546.
13.
DongX, SwaminathanS, BachmanLA, et al.Resident dendritic cells are the predominant TNF-secreting cell in early renal ischemia-reperfusion injury. Kidney Int, 2007; 71:619–628.
14.
DoudnaJA.The promise and challenge of therapeutic genome editing. Nature, 2020; 578:229–236.
15.
FarrisAB, AlpersCE. What is the best way to measure renal fibrosis? A pathologist's perspective. Kidney Int Suppl (2011), 2014; 4:9–15.
16.
GandolfoMT, JangHR, BagnascoSM, et al.Foxp3+ regulatory T cells participate in repair of ischemic acute kidney injury. Kidney Int, 2009; 76:717–729.
17.
Gharaie FathabadS, KurzhagenJT, SadasivamM, et al.T lymphocytes in acute kidney injury and repair. Semin Nephrol, 2020; 40:114–125.
18.
GillmoreJD, GaneE, TaubelJ, et al.CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. N Engl J Med, 2021; 385:493–502.
19.
GuanY, NakanoD, ZhangY, et al.A mouse model of renal fibrosis to overcome the technical variability in ischaemia/reperfusion injury among operators. Sci Rep, 2019; 9:10435.
20.
GutgartsV, SathickIJ, ZhengJ, et al.Incidence and risk factors for acute and chronic kidney injury after adult cord blood transplantation. Biol Blood Marrow Transplant, 2020; 26:758–763.
21.
HerrmannSM, PerazellaMA. Immune checkpoint inhibitors and immune-related adverse renal events. Kidney Int Rep, 2020; 5:1139–1148.
22.
IshaniA, XueJL, HimmelfarbJ, et al.Acute kidney injury increases risk of ESRD among elderly. J Am Soc Nephrol, 2009; 20:223–228.
23.
JamesMT, GhaliWA, KnudtsonML, et al.Associations between acute kidney injury and cardiovascular and renal outcomes after coronary angiography. Circulation, 2011; 123:409–416.
KimJE, YouDJ, LeeC, et al.Suppression of NF-kappaB signaling by KEAP1 regulation of IKKbeta activity through autophagic degradation and inhibition of phosphorylation. Cell Signal, 2010; 22:1645–1654.
26.
KinseyGR, OkusaMD. Expanding role of T cells in acute kidney injury. Curr Opin Nephrol Hypertens, 2014; 23:9–16.
27.
KinseyGR, SharmaR, HuangL, et al.Regulatory T cells suppress innate immunity in kidney ischemia-reperfusion injury. J Am Soc Nephrol, 2009; 20:1744–1753.
28.
KongL, WangY, LuoM, et al.Prevention of streptozotocin-induced diabetic nephropathy by MG132: Possible roles of Nrf2 and IκB. Oxid Med Cell Longev, 2017; 2017:3671751.
29.
LeeJW, BaeE, KwonSH, et al.Transcriptional modulation of the T helper 17/interleukin 17 axis ameliorates renal ischemia-reperfusion injury. Nephrol Dial Transplant, 2019; 34:1481–1498.
30.
LeonardMO, KieranNE, HowellK, et al.Reoxygenation-specific activation of the antioxidant transcription factor Nrf2 mediates cytoprotective gene expression in ischemia-reperfusion injury. FASEB J, 2006; 20:2624–2626.
31.
LiuM, GrigoryevDN, CrowMT, et al.Transcription factor Nrf2 is protective during ischemic and nephrotoxic acute kidney injury in mice. Kidney Int, 2009; 76:277–285.
32.
LiuM, ReddyNM, HigbeeEM, et al.The Nrf2 triterpenoid activator, CDDO-imidazolide, protects kidneys from ischemia-reperfusion injury in mice. Kidney Int, 2014; 85:134–141.
33.
LivakKJ, SchmittgenTD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(−delta delta C(T)) method. Methods, 2001; 25:402–408.
34.
LuY, SunY, LiuZ, et al.Activation of NRF2 ameliorates oxidative stress and cystogenesis in autosomal dominant polycystic kidney disease. Sci Transl Med, 2020; 12.
35.
MarquesVP, GoncalvesGM, FeitozaCQ, et al.Influence of TH1/TH2 switched immune response on renal ischemia-reperfusion injury. Nephron Exp Nephrol, 2006; 104:e48–e56.
36.
MehrotraP, CollettJA, McKinneySD, et al.IL-17 mediates neutrophil infiltration and renal fibrosis following recovery from ischemia reperfusion: Compensatory role of natural killer cells in athymic rats. Am J Physiol Renal Physiol, 2017; 312:F385–F397.
37.
MehrotraP, SturekM, NeyraJA, et al.Calcium channel Orai1 promotes lymphocyte IL17 expression and progressive kidney injury. J Clin Invest, 2019; 129:4951–4961.
38.
MichlitsG, HubmannM, WuSH, et al.CRISPR-UMI: Single-cell lineage tracing of pooled CRISPR-Cas9 screens. Nat Methods, 2017; 14:1191–1197.
39.
MiyagiA, LuA, HumphreysBD. Gene editing: Powerful new tools for nephrology research and therapy. J Am Soc Nephrol, 2016; 27:2940–2947.
40.
MorganE, VarroR, SepulvedaH, et al.Cytometric bead array: A multiplexed assay platform with applications in various areas of biology. Clin Immunol, 2004; 110:252–266.
NezuM, SuzukiN, YamamotoM. Targeting the KEAP1-NRF2 system to prevent kidney disease progression. Am J Nephrol, 2017b;45:473–483.
43.
NoelS, LeeSA, SadasivamM, et al.KEAP1 editing using CRISPR/Cas9 for therapeutic NRF2 activation in primary human T lymphocytes. J Immunol, 2018; 200:1929–1936.
44.
NoelS, MartinaMN, BandapalleS, et al.T lymphocyte-specific activation of Nrf2 protects from AKI. J Am Soc Nephrol, 2015; 26:2989–3000.
45.
NüssingS, HouseIG, KearneyCJ, et al.Efficient CRISPR/Cas9 gene editing in uncultured naive mouse T cells for in vivo studies. J Immunol, 2020; 204:2308–2315.
46.
O'DonnellMP, BurneM, DanielsF, et al.Utility and limitations of serum creatinine as a measure of renal function in experimental renal ischemia-reperfusion injury. Transplantation, 2002; 73:1841–1844.
47.
OhlK, TenbrockK. Oxidative stress in SLE T cells, is NRF2 really the target to treat?. Front Immunol, 2021; 12:633845.
48.
PechmanKR, De MiguelC, LundH, et al.Recovery from renal ischemia-reperfusion injury is associated with altered renal hemodynamics, blunted pressure natriuresis, and sodium-sensitive hypertension. Am J Physiol Regul Integr Comp Physiol, 2009; 297:R1358–R1363.
49.
PedruzziLM, Stockler-PintoMB, LeiteMJr, et al.Nrf2-keap1 system versus NF-κB: The good and the evil in chronic kidney disease?. Biochimie, 2012; 94:2461–2466.
50.
RabbH, DanielsF, O'DonnellM, et al.Pathophysiological role of T lymphocytes in renal ischemia-reperfusion injury in mice. Am J Physiol Renal Physiol, 2000; 279:F525–F531.
51.
RabbH, RamirezG, SabaSR, et al.Renal ischemic-reperfusion injury in L-selectin-deficient mice. Am J Physiol, 1996; 271:F408–F413.
52.
RomanJ, RangasamyT, GuoJ, et al.T-cell activation under hypoxic conditions enhances IFN-gamma secretion. Am J Respir Cell Mol Biol, 2010; 42:123–128.
53.
RushBM, BondiCD, StockerSD, et al.Genetic or pharmacologic Nrf2 activation increases proteinuria in chronic kidney disease in mice. Kidney Int, 2021; 99:102–116.
54.
SekiA, RutzS. Optimized RNP transfection for highly efficient CRISPR/Cas9-mediated gene knockout in primary T cells. J Exp Med, 2018; 215:985–997.
55.
StenvinkelP, ChertowGM, DevarajanP, et al.Chronic inflammation in chronic kidney disease progression: Role of Nrf2. Kidney Int Rep, 2021; 6:1775–1787.
56.
SuzukiT, SekiS, HiramotoK, et al.Hyperactivation of Nrf2 in early tubular development induces nephrogenic diabetes insipidus. Nat Commun, 2017; 8:14577.
57.
TanRJ, ChartoumpekisDV, RushBM, et al.Keap1 hypomorphism protects against ischemic and obstructive kidney disease. Sci Rep, 2016; 6:36185.
58.
WardynJD, PonsfordAH, SandersonCM. Dissecting molecular cross-talk between Nrf2 and NF-kappaB response pathways. Biochem Soc Trans, 2015; 43:621–626.
59.
WengerRH, KurtcuogluV, ScholzCC, et al.Frequently asked questions in hypoxia research. Hypoxia (Auckl), 2015; 3:35–43.
YangSM, KaSM, HuaKF, et al.Antroquinonol mitigates an accelerated and progressive IgA nephropathy model in mice by activating the Nrf2 pathway and inhibiting T cells and NLRP3 inflammasome. Free Radic Biol Med, 2013; 61:285–297.
62.
YokotaN, Burne-TaneyM, RacusenL, et al.Contrasting roles for STAT4 and STAT6 signal transduction pathways in murine renal ischemia-reperfusion injury. Am J Physiol Renal Physiol, 2003; 285:F319–F325.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
